When attempting to gauge whether or not the management of a company has the same priorities as its investors, one metric you ought to consider is the percentage of shares owned by insiders. Insiders sell their stock for many reasons, but when executives are exiting their stakes as fast as they can, it should raise some eyebrows.
Moderna (NASDAQ: MRNA) has experienced a renaissance since the COVID-19 pandemic intensified in March. The stock, trading under $20 per share in February, has several times approached or exceeded $80 in the months since. However, company executives aren't waiting to see what happens with their coronavirus vaccine candidate: Instead, they are taking advantage and cashing in.
Image source: Getty Images
Source Fool.com